Topics: ADHD | Atomoxetine | stimulant | Stimulants

From ADHD to off-label uses, we detail how to dose atomoxetine, how pharmacogenomic testing affects it, and how it compares with stimulants and the other antidepressant for ADHD, viloxazine (Qelbree).

Topics: Adult ADHD | Bipolar II | Borderline Personality Disorder | BPD | Diagnosis | DSM | PTSD | Stigma

Joel Paris explains why adult ADHD, depression, bipolar II, PTSD, and borderline personality are overdiagnosed in psychiatry at the expense of schizophrenia.

Topics: Antidepressant Augmentation | Antidepressants | Depression | Depressive Disorder | Novel Medications | Psilocybin | Treatment-Resistant Depression

Psilocybin is inching its way toward FDA approval in depression, but will this trial from the New England Journal of Medicine help it along or set it back?

Topics: ECT | Esketamine | Ketamine | Suicide | Treatment-Resistant Depression

The first head-to-head comparison reveals a subtle difference between these two therapies

Topics: GeneSight | Genetic Testing | Genetics and Psychiatry | Pharmacogenomics | Randomized controlled trial | Research | Research Update

Randomized controlled trials have not been kind to commercial pharmacogenetic panels, but will Genecept’s fate be any different?

Topics: DSM | Overdiagnosis

In 1974, Drs. Donald Goodwin and Samuel Guze put forth a radical idea. They wanted to pare down the unwieldy list of psychiatric diagnoses to only the most valid

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.